Mouse models for studying angiogenesis and lymphangiogenesis in cancer

Molecular Oncology

Volumn 7, Issue 2, 2013, Pages 259-282

  Eklund, Lauri ^a   Bry, Maija ^b   Alitalo, Kari ^b  

^a UNIVERSITY OF OULU   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Angiopoietin Tie; Anti angiogenesis; Endothelial cell; Mouse models for cancer; Tumor angiogenesis; Tumor imaging; Tumor lymphangiogenesis; VEGF VEGFR

Indexed keywords

BEVACIZUMAB; CRE RECOMBINASE; GELATINASE B; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1; IMATINIB; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; SEMAPHORIN 3A; SONIC HEDGEHOG PROTEIN; SORAFENIB; SUNITINIB; THROMBOSPONDIN 1; VASCULOTROPIN ANTIBODY; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANTIANGIOGENIC THERAPY; BIOAVAILABILITY; BREAST CARCINOMA; CANCER GROWTH; CANCER TRANSPLANTATION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INVASION; CELL POPULATION; CHEMICAL CARCINOGENESIS; CHROMOSOME ABERRATION; CLINICAL TRIAL (TOPIC); COLON ADENOCARCINOMA; COLON CARCINOMA; CONFOCAL MICROSCOPY; DISEASE MODEL; DNA MODIFICATION; EMBRYONIC STEM CELL; ENDOCRINE TUMOR; ENDOTHELIAL PROGENITOR CELL; FLUORESCENCE MICROSCOPY; GENE DELETION; GENETIC DISORDER; GENETIC ENGINEERING; GENETIC MODEL; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; LEWIS CARCINOMA; LYMPHANGIOGENESIS; MELANOMA B16; METASTASIS; MICROSCOPY; MOLECULARLY TARGETED THERAPY; MULTIPHOTON MICROSCOPY; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; ONCOGENE H RAS; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL TOMOGRAPHY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS ISLET CELL TUMOR; PHOTOACOUSTIC TOMOGRAPHY; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SOMATIC CELL; SOMATIC MUTATION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; WNT SIGNALING PATHWAY;

MAMMALIA; MUS;

EID: 84875809217     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.02.007     Document Type: Review

References (228)

1. Abedin Z.R., Ma Z., Reddy E.P. Increased angiogenesis in Cdk4(R24C/R24C):Apc(+/Min) intestinal tumors. Cell Cycle 2010, 9:2456-2463.
2. Abel E.L., Angel J.M., Kiguchi K., DiGiovanni J. Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. Nat. Protoc. 2009, 4:1350-1362.
3. Abengozar M.A., de Frutos S., Ferreiro S., et al. Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth. Blood 2012, 119:4565-4576.
4. Aguirre A.J., Bardeesy N., Sinha M., Lopez L., Tuveson D.A., Horner J., Redston M.S., DePinho R.A. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003, 17:3112-3126.
5. Akerblom B., Zang G., Zhuang Z.W., Calounova G., Simons M., Welsh M. Heterogeneity among RIP-Tag2 insulinomas allows vascular endothelial growth factor-A independent tumor expansion as revealed by studies in Shb mutant mice: implications for tumor angiogenesis. Mol. Oncol. 2012, 6:333-346.
6. Akino T., Hida K., Hida Y., et al. Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am. J. Pathol. 2009, 175:2657-2667.
7. Alferez D., Wilkinson R.W., Watkins J., et al. Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc(Min/+) mice. Mol. Cancer Ther. 2008, 7:590-598.
8. Alitalo A., Detmar M. Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene 2012, 31:4499-4508.
9. Alitalo K. The lymphatic vasculature in disease. Nat. Med. 2011, 17:1371-1380.
10. Alva J.A., Zovein A.C., Monvoisin A., Murphy T., Salazar A., Harvey N.L., Carmeliet P., Iruela-Arispe M.L. VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells. Dev. Dyn. 2006, 235:759-767.
11. Baffert F., Le T., Sennino B., Thurston G., Kuo C.J., Hu-Lowe D., McDonald D.M. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H547-H559.
12. Bais C., Wu X., Yao J., et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010, 141:166-177.
13. Barker N., Ridgway R.A., van Es J.H., van de Wetering M., Begthel H., van den Born M., Danenberg E., Clarke A.R., Sansom O.J., Clevers H. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009, 457:608-611.
14. Bassi A., Fieramonti L., D'Andrea C., Mione M., Valentini G. In vivo label-free three-dimensional imaging of zebrafish vasculature with optical projection tomography. J. Biomed. Opt. 2011, 16:100502.
15. Bazigou E., Lyons O.T., Smith A., Venn G.E., Cope C., Brown N.A., Makinen T. Genes regulating lymphangiogenesis control venous valve formation and maintenance in mice. J. Clin. Invest. 2011, 121:2984-2992.
16. Bekes E.M., Schweighofer B., Kupriyanova T.A., Zajac E., Ardi V.C., Quigley J.P., Deryugina E.I. Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. Am. J. Pathol. 2011, 179:1455-1470.
17. Belur L.R., Podetz-Pedersen K.M., Sorenson B.S., Hsu A.H., Parker J.B., Carlson C.S., Saltzman D.A., Ramakrishnan S., McIvor R.S. Inhibition of angiogenesis and suppression of colorectal cancer metastatic to the liver using the sleeping beauty transposon system. Mol. Cancer 2011, 10. 14-4598-10-14.
18. Bergers G., Brekken R., McMahon G., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2000, 2:737-744.
19. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
20. Bergers G., Javaherian K., Lo K.M., Folkman J., Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999, 284:808-812.
21. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 2003, 111:1287-1295.
22. Boivin G.P., Washington K., Yang K., et al. Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 2003, 124:762-777.
23. Brown E.B., Campbell R.B., Tsuzuki Y., Xu L., Carmeliet P., Fukumura D., Jain R.K. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat. Med. 2001, 7:864-868.
24. Brown J.L., Cao Z.A., Pinzon-Ortiz M., et al. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol. Cancer Ther. 2010, 9:145-156.
25. Burton J.B., Priceman S.J., Sung J.L., Brakenhielm E., An D.S., Pytowski B., Alitalo K., Wu L. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res. 2008, 68:7828-7837.
26. Caduff J.H., Fischer L.C., Burri P.H. Scanning electron microscope study of the developing microvasculature in the postnatal rat lung. Anat. Rec. 1986, 216:154-164.
27. Cao Y., Sonveaux P., Liu S., Zhao Y., Mi J., Clary B.M., Li C.Y., Kontos C.D., Dewhirst M.W. Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cancer Res. 2007, 67:3835-3844.
28. Carmeliet P., Jain R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 2011, 10:417-427.
29. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
30. Caunt M., Mak J., Liang W.C., et al. Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 2008, 13:331-342.
31. Cheon D.J., Orsulic S. Mouse models of cancer. Annu. Rev. Pathol. 2011, 6:95-119.
32. Choi I., Chung H.K., Ramu S., et al. Visualization of lymphatic vessels by Prox1-promoter directed GFP reporter in a bacterial artificial chromosome-based transgenic mouse. Blood 2011, 117:362-365.
33. Christoffersson G., Vagesjo E., Vandooren J., Liden M., Massena S., Reinert R.B., Brissova M., Powers A.C., Opdenakker G., Phillipson M. VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. Blood 2012, 120:4653-4662.
34. Chung A.S., Ferrara N. Developmental and pathological angiogenesis. Annu. Rev. Cell. Dev. Biol. 2011, 27:563-584.
35. Chung A.S., Kowanetz M., Wu X., Zhuang G., Ngu H., Finkle D., Komuves L., Peale F., Ferrara N. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J. Pathol. 2012, 227:404-416.
36. Claxton S., Kostourou V., Jadeja S., Chambon P., Hodivala-Dilke K., Fruttiger M. Efficient, inducible Cre-recombinase activation in vascular endothelium. Genesis 2008, 46:74-80.
37. Cook N., Frese K.K., Bapiro T.E., et al. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J. Exp. Med. 2012, 209:437-444.
38. Coussens L.M., Hanahan D., Arbeit J.M. Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am. J. Pathol. 1996, 149:1899-1917.
39. Crabtree J.S., Scacheri P.C., Ward J.M., et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc. Natl. Acad. Sci. U S A 2001, 98:1118-1123.
40. Crawford Y., Ferrara N. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol. Sci. 2009, 30:624-630.
41. Crawford Y., Ferrara N. VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res. 2009, 335:261-269.
42. Daly C., Eichten A., Castanaro C., et al. Angiopoietin-2 functions as a tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2013, 73:108-118.
43. De Palma M., Venneri M.A., Galli R., Sergi Sergi L., Politi L.S., Sampaolesi M., Naldini L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8:211-226.
44. Detry B., Erpicum C., Paupert J., et al. Matrix metalloproteinase-2 governs lymphatic vessel formation as an interstitial collagenase. Blood 2012, 119:5048-5056.
45. di Tomaso E., Capen D., Haskell A., Hart J., Logie J.J., Jain R.K., McDonald D.M., Jones R., Munn L.L. Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers. Cancer Res. 2005, 65:5740-5749.
46. Dong J., Zhang Q., Huang Q., et al. Glioma stem cells involved in tumor tissue remodeling in a xenograft model. J. Neurosurg. 2010, 113:249-260.
47. Dranoff G. Experimental mouse tumour models: what can be learnt about human cancer immunology?. Nat. Rev. Immunol. 2011, 12:61-66.
48. Duong T., Proulx S.T., Luciani P., Leroux J.C., Detmar M., Koopman P., Francois M. Genetic ablation of SOX18 function suppresses tumor lymphangiogenesis and metastasis of melanoma in mice. Cancer Res. 2012, 72:3105-3114.
49. Ebos J.M., Kerbel R.S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 2011, 8:210-221.
50. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
51. Erturk A., Becker K., Jahrling N., Mauch C.P., Hojer C.D., Egen J.G., Hellal F., Bradke F., Sheng M., Dodt H.U. Three-dimensional imaging of solvent-cleared organs using 3DISCO. Nat. Protoc. 2012, 7:1983-1995.
52. Fagiani E., Lorentz P., Kopfstein L., Christofori G. Angiopoietin-1 and -2 exert antagonistic functions in tumor angiogenesis, yet both induce lymphangiogenesis. Cancer Res. 2011, 71:5717-5727.
53. Fang S., Salven P. Stem cells in tumor angiogenesis. J. Mol. Cell. Cardiol. 2011, 50:290-295.
54. Fang S., Wei J., Pentinmikko N., Leinonen H., Salven P. Generation of functional blood vessels from a single c-kit+ adult vascular endothelial stem cell. PLoS Biol. 2012, 10:e1001407.
55. Farago A.F., Snyder E.L., Jacks T. SnapShot: lung cancer models. Cell 2012, 149:246-246.e1.
56. Feil R., Brocard J., Mascrez B., LeMeur M., Metzger D., Chambon P. Ligand-activated site-specific recombination in mice. Proc. Natl. Acad. Sci. U S A 1996, 93:10887-10890.
57. Fischer C., Jonckx B., Mazzone M., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
58. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
59. Francescone R., Scully S., Bentley B., Yan W., Taylor S.L., Oh D., Moral L., Shao R. Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation. J. Biol. Chem. 2012, 287:24821-24831.
60. Francia G., Cruz-Munoz W., Man S., Xu P., Kerbel R.S. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat. Rev. Cancer 2011, 11:135-141.
61. Francia G., Kerbel R.S. Raising the bar for cancer therapy models. Nat. Biotechnol. 2010, 28:561-562.
62. Fu Y., Tang H., Huang Y., Song N., Luo Y. Unraveling the mysteries of endostatin. IUBMB Life 2009, 61:613-626.
63. Fukumura D., Duda D.G., Munn L.L., Jain R.K. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation 2010, 17:206-225.
64. Fukumura D., Jain R.K. Imaging angiogenesis and the microenvironment. APMIS 2008, 116:695-715.
65. Gale N.W., Thurston G., Hackett S.F., et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev. Cell 2002, 3:411-423.
66. Ganss R., Hanahan D. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res. 1998, 58:4673-4681.
67. Gao D., Nolan D.J., Mellick A.S., Bambino K., McDonnell K., Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008, 319:195-198.
68. Gerber H.P., Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005, 65:671-680.
69. Gerber H.P., Wu X., Yu L., et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc. Natl. Acad. Sci. U S A 2007, 104:3478-3483.
70. Giavazzi R., Giuliani R., Coltrini D., Bani M.R., Ferri C., Sennino B., Tosatti M.P., Stoppacciaro A., Presta M. Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors. Cancer Res. 2001, 61:309-317.
71. Goodlad R.A., Ryan A.J., Wedge S.R., Pyrah I.T., Alferez, Poulsom R., Smith N.R., Mandir N., Watkins A.J., Wilkinson R.W. Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer. Carcinogenesis 2006, 27:2133-2139.
72. Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. U S A 1992, 89:5547-5551.
73. Greenberg N.M., DeMayo F., Finegold M.J., Medina D., Tilley W.D., Aspinall J.O., Cunha G.R., Donjacour A.A., Matusik R.J., Rosen J.M. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. U S A 1995, 92:3439-3443.
74. Gustafsson E., Brakebusch C., Hietanen K., Fassler R. Tie-1-directed expression of Cre recombinase in endothelial cells of embryoid bodies and transgenic mice. J. Cell Sci. 2001, 114:671-676.
75. Gutierrez L.S., Suckow M., Lawler J., Ploplis V.A., Castellino F.J. Thrombospondin 1-a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model. Carcinogenesis 2003, 24:199-207.
76. Guy C.T., Muthuswamy S.K., Cardiff R.D., Soriano P., Muller W.J. Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev. 1994, 8:23-32.
77. Hagerling R., Pollmann C., Kremer L., Andresen V., Kiefer F. Intravital two-photon microscopy of lymphatic vessel development and function using a transgenic Prox1 promoter-directed mOrange2 reporter mouse. Biochem. Soc. Trans. 2011, 39:1674-1681.
78. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985, 315:115-122.
79. Hanahan D., Wagner E.F., Palmiter R.D. The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. Genes Dev. 2007, 21:2258-2270.
80. Hayes D.F. Bevacizumab treatment for solid tumors: boon or bust?. JAMA 2011, 305:506-508.
81. He Y., Rajantie I., Pajusola K., Jeltsch M., Holopainen T., Yla-Herttuala S., Harding T., Jooss K., Takahashi T., Alitalo K. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 2005, 65:4739-4746.
82. Hingorani S.R., Wang L., Multani A.S., Combs C., Deramaudt T.B., Hruban R.H., Rustgi A.K., Chang S., Tuveson D.A. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005, 7:469-483.
83. Hlushchuk R., Riesterer O., Baum O., Wood J., Gruber G., Pruschy M., Djonov V. Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation. Am. J. Pathol. 2008, 173:1173-1185.
84. Hoffman J.A., Giraudo E., Singh M., Zhang L., Inoue M., Porkka K., Hanahan D., Ruoslahti E. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell 2003, 4:383-391.
85. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., Yancopoulos G.D., Wiegand S.J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-1998.
86. Holleran J.L., Miller C.J., Culp L.A. Tracking micrometastasis to multiple organs with lacZ-tagged CWR22R prostate carcinoma cells. J. Histochem. Cytochem. 2000, 48:643-651.
87. Holopainen T., Saharinen P., D'Amico G., et al. Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J. Natl. Cancer Inst. 2012, 104:461-475.
88. Horiguchi Y., Larchian W.A., Kaplinsky R., Fair W.R., Heston W.D. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther. 2000, 7:844-851.
89. Huijbers I.J., Krimpenfort P., Berns A., Jonkers J. Rapid validation of cancer genes in chimeras derived from established genetically engineered mouse models. Bioessays 2011, 33:701-710.
90. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
91. Iljin K., Petrova T.V., Veikkola T., Kumar V., Poutanen M., Alitalo K. A fluorescent Tie1 reporter allows monitoring of vascular development and endothelial cell isolation from transgenic mouse embryos. FASEB J. 2002, 16:1764-1774.
92. Indra A.K., Warot X., Brocard J., Bornert J.M., Xiao J.H., Chambon P., Metzger D. Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases. Nucleic Acids Res. 1999, 27:4324-4327.
93. Inoue M., Hager J.H., Ferrara N., Gerber H.P., Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002, 1:193-202.
94. Jackson E.L., Olive K.P., Tuveson D.A., Bronson R., Crowley D., Brown M., Jacks T. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 2005, 65:10280-10288.
95. Jahrling N., Becker K., Dodt H.U. 3D-reconstruction of blood vessels by ultramicroscopy. Organogenesis 2009, 5:145-148.
96. Jain R.K. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat. Rev. Cancer 2008, 8:309-316.
97. Joyce J.A., Baruch A., Chehade K., Meyer-Morse N., Giraudo E., Tsai F.Y., Greenbaum D.C., Hager J.H., Bogyo M., Hanahan D. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 2004, 5:443-453.
98. Joyce J.A., Freeman C., Meyer-Morse N., Parish C.R., Hanahan D. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 2005, 24:4037-4051.
99. Joyce J.A., Laakkonen P., Bernasconi M., Bergers G., Ruoslahti E., Hanahan D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2003, 4:393-403.
100. Jung Y., Zhi Z., Wang R.K. Three-dimensional optical imaging of microvascular networks within intact lymph node in vivo. J. Biomed. Opt. 2010, 15:050501.
101. Kalaitzidis D., Armstrong S.A. Cancer: the flipside of Notch. Nature 2011, 473:159-160.
102. Karnezis T., Shayan R., Caesar C., et al. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell 2012, 21:181-195.
103. Karpanen T., Egeblad M., Karkkainen M.J., Kubo H., Yla-Herttuala S., Jaattela M., Alitalo K. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 2001, 61:1786-1790.
104. Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 2004, 4:423-436.
105. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
106. Kim M., Koh Y.J., Kim K.E., Koh B.I., Nam D.H., Alitalo K., Kim I., Koh G.Y. CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res. 2010, 70:10411-10421.
107. Kisanuki Y.Y., Hammer R.E., Miyazaki J., Williams S.C., Richardson J.A., Yanagisawa M. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev. Biol. 2001, 230:230-242.
108. Kopfstein L., Veikkola T., Djonov V.G., Baeriswyl V., Schomber T., Strittmatter K., Stacker S.A., Achen M.G., Alitalo K., Christofori G. Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis. Am. J. Pathol. 2007, 170:1348-1361.
109. Korsisaari N., Kasman I.M., Forrest W.F., Pal N., Bai W., Fuh G., Peale F.V., Smits R., Ferrara N. Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. Proc. Natl. Acad. Sci. U S A 2007, 104:10625-10630.
110. Korsisaari N., Ross J., Wu X., et al. Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1. Clin. Cancer Res. 2008, 14:249-258.
111. Kozaki K., Miyaishi O., Tsukamoto T., Tatematsu Y., Hida T., Takahashi T., Takahashi T. Establishment and characterization of a human lung cancer cell line NCI-H460-LNM35 with consistent lymphogenous metastasis via both subcutaneous and orthotopic propagation. Cancer Res. 2000, 60:2535-2540.
112. Kubota Y., Takubo K., Shimizu T., Ohno H., Kishi K., Shibuya M., Saya H., Suda T. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J. Exp. Med. 2009, 206:1089-1102.
113. Kusters B., Leenders W.P., Wesseling P., Smits D., Verrijp K., Ruiter D.J., Peters J.P., van Der Kogel A.J., de Waal R.M. Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res. 2002, 62:341-345.
114. Laufer J., Johnson P., Zhang E., Treeby B., Cox B., Pedley B., Beard P. In vivo preclinical photoacoustic imaging of tumor vasculature development and therapy. J. Biomed. Opt. 2012, 17:056016.
115. Lazarus A., Keshet E. Vascular endothelial growth factor and vascular homeostasis. Proc. Am. Thorac. Soc. 2011, 8:508-511.
116. Lee S., Chen T.T., Barber C.L., Jordan M.C., Murdock J., Desai S., Ferrara N., Nagy A., Roos K.P., Iruela-Arispe M.L. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007, 130:691-703.
117. Lewis C.E., Ferrara N. Multiple effects of angiopoietin-2 blockade on tumors. Cancer Cell 2011, 19:431-433.
118. Licht A.H., Raab S., Hofmann U., Breier G. Endothelium-specific Cre recombinase activity in flk-1-Cre transgenic mice. Dev. Dyn. 2004, 229:312-318.
119. Lin E.Y., Li J.F., Bricard G., Wang W., Deng Y., Sellers R., Porcelli S.A., Pollard J.W. Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol. Oncol. 2007, 1:288-302.
120. Lin E.Y., Li J.F., Gnatovskiy L., Deng Y., Zhu L., Grzesik D.A., Qian H., Xue X.N., Pollard J.W. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 2006, 66:11238-11246.
121. Lin J., Lalani A.S., Harding T.C., et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res. 2005, 65:6901-6909.
122. Loges S., Mazzone M., Hohensinner P., Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009, 15:167-170.
123. Lohela M., Helotera H., Haiko P., Dumont D.J., Alitalo K. Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues. Am. J. Pathol. 2008, 173:1891-1901.
124. Loi M., Di Paolo D., Becherini P., et al. The use of the orthotopic model to validate antivascular therapies for cancer. Int. J. Dev. Biol. 2011, 55:547-555.
125. Lunt S.J., Gray C., Reyes-Aldasoro C.C., Matcher S.J., Tozer G.M. Application of intravital microscopy in studies of tumor microcirculation. J. Biomed. Opt. 2010, 15:011113.
126. Lyden D., Hattori K., Dias S., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 2001, 7:1194-1201.
127. Lyden D., Young A.Z., Zagzag D., et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 1999, 401:670-677.
128. Maione F., Capano S., Regano D., Zentilin L., Giacca M., Casanovas O., Bussolino F., Serini G., Giraudo E. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J. Clin. Invest. 2012, 122:1832-1848.
129. Maione F., Molla F., Meda C., Latini R., Zentilin L., Giacca M., Seano G., Serini G., Bussolino F., Giraudo E. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J. Clin. Invest. 2009, 119:3356-3372.
130. Maisonpierre P.C., Suri C., Jones P.F., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60.
131. Mancuso M.R., Davis R., Norberg S.M., et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 2006, 116:2610-2621.
132. Mandriota S.J., Jussila L., Jeltsch M., et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001, 20:672-682.
133. Maniotis A.J., Folberg R., Hess A., Seftor E.A., Gardner L.M., Pe'er J., Trent J.M., Meltzer P.S., Hendrix M.J. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 1999, 155:739-752.
134. Martinez-Corral I., Olmeda D., Dieguez-Hurtado R., Tammela T., Alitalo K., Ortega S. In vivo imaging of lymphatic vessels in development, wound healing, inflammation, and tumor metastasis. Proc. Natl. Acad. Sci. U S A 2012, 109:6223-6228.
135. Marumoto T., Tashiro A., Friedmann-Morvinski D., Scadeng M., Soda Y., Gage F.H., Verma I.M. Development of a novel mouse glioma model using lentiviral vectors. Nat. Med. 2009, 15:110-116.
136. Matsui J., Funahashi Y., Uenaka T., Watanabe T., Tsuruoka A., Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin. Cancer Res. 2008, 14:5459-5465.
137. Mattila M.M., Ruohola J.K., Karpanen T., Jackson D.G., Alitalo K., Harkonen P.L. VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int. J. Cancer 2002, 98:946-951.
138. McCart A.E., Vickaryous N.K., Silver A. Apc mice: models, modifiers and mutants. Pathol. Res. Pract. 2008, 204:479-490.
139. McDonald D.M., Choyke P.L. Imaging of angiogenesis: from microscope to clinic. Nat. Med. 2003, 9:713-725.
140. McMillan R., Matsui W. Molecular pathways: the hedgehog signaling pathway in cancer. Clin. Cancer Res. 2012, 18:4883-4888.
141. Moser A.R., Mattes E.M., Dove W.F., Lindstrom M.J., Haag J.D., Gould M.N. ApcMin, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias. Proc. Natl. Acad. Sci. U S A 1993, 90:8977-8981.
142. Motoike T., Loughna S., Perens E., et al. Universal GFP reporter for the study of vascular development. Genesis 2000, 28:75-81.
143. Moussai D., Mitsui H., Pettersen J.S., Pierson K.C., Shah K.R., Suarez-Farinas M., Cardinale I.R., Bluth M.J., Krueger J.G., Carucci J.A. The human cutaneous squamous cell carcinoma microenvironment is characterized by increased lymphatic density and enhanced expression of macrophage-derived VEGF-C. J. Invest. Dermatol. 2011, 131:229-236.
144. Moy A.J., White S.M., Indrawan E.S., et al. Wide-field functional imaging of blood flow and hemoglobin oxygen saturation in the rodent dorsal window chamber. Microvasc. Res. 2011, 82:199-209.
145. Nagy J.A., Chang S.H., Shih S.C., Dvorak A.M., Dvorak H.F. Heterogeneity of the tumor vasculature. Semin. Thromb. Hemost. 2010, 36:321-331.
146. Nasarre P., Thomas M., Kruse K., Helfrich I., Wolter V., Deppermann C., Schadendorf D., Thurston G., Fiedler U., Augustin H.G. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res. 2009, 69:1324-1333.
147. Nathke I.S. The adenomatous polyposis coli protein: the Achilles heel of the gut epithelium. Annu. Rev. Cell. Dev. Biol. 2004, 20:337-366.
148. Niessen K., Zhang G., Ridgway J.B., Chen H., Kolumam G., Siebel C.W., Yan M. The Notch1-Dll4 signaling pathway regulates mouse postnatal lymphatic development. Blood 2011, 118:1989-1997.
149. Niland S., Eble J.A. Integrin-mediated cell-matrix interaction in physiological and pathological blood vessel formation. J.Oncol. 2012, 2012:125278.
150. Nozawa H., Chiu C., Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl. Acad. Sci. U S A 2006, 103:12493-12498.
151. Oladipupo S., Hu S., Kovalski J., Yao J., Santeford A., Sohn R.E., Shohet R., Maslov K., Wang L.V., Arbeit J.M. VEGF is essential for hypoxia-inducible factor-mediated neovascularization but dispensable for endothelial sprouting. Proc. Natl. Acad. Sci. U S A 2011, 108:13264-13269.
152. Oladipupo S.S., Hu S., Santeford A.C., Yao J., Kovalski J.R., Shohet R.V., Maslov K., Wang L.V., Arbeit J.M. Conditional HIF-1 induction produces multistage neovascularization with stage-specific sensitivity to VEGFR inhibitors and myeloid cell independence. Blood 2011, 117:4142-4153.
153. Oliner J., Min H., Leal J., et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004, 6:507-516.
154. Olive K.P., Jacobetz M.A., Davidson C.J., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
155. Olson P., Chu G.C., Perry S.R., Nolan-Stevaux O., Hanahan D. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc. Natl. Acad. Sci. U S A 2011, 108:E1275-E1284.
156. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
157. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79:315-328.
158. Padera T.P., Kadambi A., di Tomaso E., et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002, 296:1883-1886.
159. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
160. Paku S., Dezso K., Bugyik E., Tovari J., Timar J., Nagy P., Laszlo V., Klepetko W., Dome B. A new mechanism for pillar formation during tumor-induced intussusceptive angiogenesis: inverse sprouting. Am. J. Pathol. 2011, 179:1573-1585.
161. Palmer G.M., Fontanella A.N., Shan S., Hanna G., Zhang G., Fraser C.L., Dewhirst M.W. In vivo optical molecular imaging and analysis in mice using dorsal window chamber models applied to hypoxia, vasculature and fluorescent reporters. Nat. Protoc. 2011, 6:1355-1366.
162. Patan S., Munn L.L., Jain R.K. Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Microvasc. Res. 1996, 51:260-272.
163. Perez-Mancera P.A., Guerra C., Barbacid M., Tuveson D.A. What we have learned about pancreatic cancer from mouse models. Gastroenterology 2012, 142:1079-1092.
164. Pham T.H., Baluk P., Xu Y., Grigorova I., Bankovich A.J., Pappu R., Coughlin S.R., McDonald D.M., Schwab S.R., Cyster J.G. Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. J. Exp. Med. 2010, 207:17-27.
165. Potente M., Gerhardt H., Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011, 146:873-887.
166. Price J.E., Polyzos A., Zhang R.D., Daniels L.M. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res. 1990, 50:717-721.
167. Quintana E., Piskounova E., Shackleton M., Weinberg D., Eskiocak U., Fullen D.R., Johnson T.M., Morrison S.J. Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. Sci. Trans. Med. 2012, 4. 159ra149.
168. Quintana L., Sharpe J. Preparation of mouse embryos for optical projection tomography imaging. Cold Spring Harb Protoc. 2011, 2011:664-669.
169. Rafii S., Lyden D. Cancer. A few to flip the angiogenic switch. Science 2008, 319:163-164.
170. Ribatti D., Djonov V. Intussusceptive microvascular growth in tumors. Cancer Lett. 2012, 316:126-131.
171. Ricci-Vitiani L., Pallini R., Biffoni M., et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468:824-828.
172. Rinkevich Y., Lindau P., Ueno H., Longaker M.T., Weissman I.L. Germ-layer and lineage-restricted stem/progenitors regenerate the mouse digit tip. Nature 2011, 476:409-413.
173. Roberts N., Kloos B., Cassella M., Podgrabinska S., Persaud K., Wu Y., Pytowski B., Skobe M. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res. 2006, 66:2650-2657.
174. Rohan R.M., Fernandez A., Udagawa T., Yuan J., D'Amato R.J. Genetic heterogeneity of angiogenesis in mice. FASEB J. 2000, 14:871-876.
175. Saharinen P., Eklund L., Pulkki K., Bono P., Alitalo K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol. Med. 2011, 17:347-362.
176. Sakariassen P.O., Prestegarden L., Wang J., et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc. Natl. Acad. Sci. U S A 2006, 103:16466-16471.
177. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., Lilenbaum R., Johnson D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 355:2542-2550.
178. Schulz P., Fischer C., Detjen K.M., et al. Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer. FASEB J. 2011, 25:3325-3335.
179. Scully S., Francescone R., Faibish M., Bentley B., Taylor S.L., Oh D., Schapiro R., Moral L., Yan W., Shao R. Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas. J. Neurosci. 2012, 32:12950-12960.
180. Seaman S., Stevens J., Yang M.Y., Logsdon D., Graff-Cherry C., St Croix B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007, 11:539-554.
181. Sennino B., Ishiguro-Oonuma T., Wei Y., et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov. 2012, 2:270-287.
182. Shaifer C.A., Huang J., Lin P.C. Glioblastoma cells incorporate into tumor vasculature and contribute to vascular radioresistance. Int. J. Cancer 2010, 127:2063-2075.
183. Shchors K., Evan G. Tumor angiogenesis: cause or consequence of cancer?. Cancer Res. 2007, 67:7059-7061.
184. Shchors K., Shchors E., Rostker F., Lawlor E.R., Brown-Swigart L., Evan G.I. The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes Dev. 2006, 20:2527-2538.
185. Shields J.D., Emmett M.S., Dunn D.B., Joory K.D., Sage L.M., Rigby H., Mortimer P.S., Orlando A., Levick J.R., Bates D.O. Chemokine-mediated migration of melanoma cells towards lymphatics-a mechanism contributing to metastasis. Oncogene 2007, 26:2997-3005.
186. Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett. 2012, 320:130-137.
187. Sica A., Allavena P., Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett. 2008, 267:204-215.
188. Singh M., Couto S.S., Forrest W.F., et al. Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. J. Pathol. 2012, 227:417-430.
189. Singh M., Ferrara N. Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat. Biotechnol. 2012, 30:648-657.
190. Singh M., Lima A., Molina R., et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat. Biotechnol. 2010, 28:585-593.
191. Singh M., Murriel C.L., Johnson L. Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes. Cancer Res. 2012, 72:2695-2700.
192. Skobe M., Hamberg L.M., Hawighorst T., Schirner M., Wolf G.L., Alitalo K., Detmar M. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am. J. Pathol. 2001, 159:893-903.
193. Skobe M., Hawighorst T., Jackson D.G., Prevo R., Janes L., Velasco P., Riccardi L., Alitalo K., Claffey K., Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 2001, 7:192-198.
194. Sleeman J.P., Thiele W. Tumor metastasis and the lymphatic vasculature. Int. J. Cancer 2009, 125:2747-2756.
195. Soda Y., Marumoto T., Friedmann-Morvinski D., et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc. Natl. Acad. Sci. U S A 2011, 108:4274-4280.
196. Sorensen I., Adams R.H., Gossler A. DLL1-mediated notch activation regulates endothelial identity in mouse fetal arteries. Blood 2009, 113:5680-5688.
197. Sorg B.S., Moeller B.J., Donovan O., Cao Y., Dewhirst M.W. Hyperspectral imaging of hemoglobin saturation in tumor microvasculature and tumor hypoxia development. J. Biomed. Opt. 2005, 10:44004.
198. Spring H., Schuler T., Arnold B., Hammerling G.J., Ganss R. Chemokines direct endothelial progenitors into tumor neovessels. Proc. Natl. Acad. Sci. U S A 2005, 102:18111-18116.
199. Stacker S.A., Caesar C., Baldwin M.E., Thornton G.E., Williams R.A., Prevo R., Jackson D.G., Nishikawa S., Kubo H., Achen M.G. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 2001, 7:186-191.
200. Sung Y.H., Baek I.J., Kim D.H., Jeon J., Lee J., Lee K., Jeong D., Kim J.S., Lee H.W. Knockout mice created by TALEN-mediated gene targeting. Nat. Biotechnol. 2013, 31:23-24.
201. Tammela T., Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 2010, 140:460-476.
202. Tammela T., Saaristo A., Holopainen T., Yla-Herttuala S., Andersson L.C., Virolainen S., Immonen I., Alitalo K. Photodynamic ablation of lymphatic vessels and intralymphatic cancer cells prevents metastasis. Sci. Trans. Med. 2011, 3. 69ra11.
203. Tammela T., Zarkada G., Wallgard E., et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008, 454:656-660.
204. Thurston G., Daly C. The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway. Cold Spring Harb Perspect. Med. 2012, 2:a006550.
205. Tomer R., Khairy K., Keller P.J. Shedding light on the system: studying embryonic development with light sheet microscopy. Curr. Opin. Genet. Dev. 2011, 21:558-565.
206. Truman L.A., Bentley K.L., Smith E.C., et al. ProxTom lymphatic vessel reporter mice reveal Prox1 expression in the adrenal medulla, megakaryocytes, and platelets. Am. J. Pathol. 2012, 180:1715-1725.
207. Tsai M.S., Chang C.C., Kuo M.L., Wu Y.T. Vascular endothelial growth factor-A and changes in a tumor-bearing mouse model with Lewis lung cancer. Oncol. Lett. 2011, 2:1143-1147.
208. Ullrich R.T., Jikeli J.F., Diedenhofen M., Bohm-Sturm P., Unruh M., Vollmar S., Hoehn M. In-vivo visualization of tumor microvessel density and response to anti-angiogenic treatment by high resolution MRI in mice. PLoS One 2011, 6:e19592.
209. Vakoc B.J., Fukumura D., Jain R.K., Bouma B.E. Cancer imaging by optical coherence tomography: preclinical progress and clinical potential. Nat. Rev. Cancer 2012, 12:363-368.
210. Vakoc B.J., Lanning R.M., Tyrrell J.A., et al. Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat. Med. 2009, 15:1219-1223.
211. Van Cutsem E., Vervenne W.L., Bennouna J., et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 2009, 27:2231-2237.
212. Van de Veire S., Stalmans I., Heindryckx F., et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010, 141:178-190.
213. van Miltenburg M.H., Jonkers J. Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches. Curr. Opin. Genet. Dev. 2012, 22:21-27.
214. Viana C.T., Campos P.P., Carvalho L.A., Cenedezi J.M., Lavall L., Lopes M.T., Ferreira M.A., Andrade S.P. Distinct types of tumors exhibit differential grade of inflammation and angiogenesis in mice. Microvasc. Res 2013, 86:44-51.
215. Wang C.A., Jedlicka P., Patrick A.N., Micalizzi D.S., Lemmer K.C., Deitsch E., Casas-Selves M., Harrell J.C., Ford H.L. SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer. J. Clin. Invest. 2012, 122:1895-1906.
216. Wang D., Stockard C.R., Harkins L., et al. Immunohistochemistry in the evaluation of neovascularization in tumor xenografts. Biotech. Histochem. 2008, 83:179-189.
217. Wang L.V., Hu S. Photoacoustic tomography: in vivo imaging from organelles to organs. Science 2012, 335:1458-1462.
218. Wang R., Chadalavada K., Wilshire J., Kowalik U., Hovinga K.E., Geber A., Fligelman B., Leversha M., Brennan C., Tabar V. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010, 468:829-833.
219. Wang Y., Nakayama M., Pitulescu M.E., et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 2010, 465:483-486.
220. Winkler F., Kienast Y., Fuhrmann M., Von Baumgarten L., Burgold S., Mitteregger G., Kretzschmar H., Herms J. Imaging glioma cell invasion in vivo reveals mechanisms of dissemination and peritumoral angiogenesis. Glia 2009, 57:1306-1315.
221. Wyckoff J., Gligorijevic B., Entenberg D., Segall J., Condeelis J. High-resolution multiphoton imaging of tumors in vivo. Cold Spring Harb Protoc. 2011, 2011:1167-1184.
222. Xian X., Hakansson J., Stahlberg A., Lindblom P., Betsholtz C., Gerhardt H., Semb H. Pericytes limit tumor cell metastasis. J. Clin. Invest. 2006, 116:642-651.
223. Xu Y., Yuan L., Mak J., et al. Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J. Cell Biol. 2010, 188:115-130.
224. Yang H., Kim C., Kim M.J., Schwendener R.A., Alitalo K., Heston W., Kim I., Kim W.J., Koh G.Y. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. Mol. Cancer 2011, 10. 36-4598-10-36.
225. Yang X., Knopp M.V. Quantifying tumor vascular heterogeneity with dynamic contrast-enhanced magnetic resonance imaging: a review. J. Biomed. Biotechnol. 2011, 2011:732848.
226. Yao J., Wu X., Zhuang G., Kasman I.M., Vogt T., Phan V., Shibuya M., Ferrara N., Bais C. Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc. Natl. Acad. Sci. U S A 2011, 108:11590-11595.
227. Yoshiji H., Harris S.R., Thorgeirsson U.P. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res. 1997, 57:3924-3928.
228. You W.K., Sennino B., Williamson C.W., Falcon B., Hashizume H., Yao L.C., Aftab D.T., McDonald D.M. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 2011, 71:4758-4768.